CytRx Corporation Культура компании

Mr. Steven A. Kriegsman, also known as Steve, founded The Kriegsman Group in 1992 and serves as its President. Mr. Kriegsman also founded Kriegsman Capital Group LLC and has been its President since 1989. He has been the Chief Executive Officer and President at Cytrx Corporation since July 2002 and served as its Interim Chief Financial Officer since June 15, 2004. He served as the Chief Executive Officer of ANA Financial until 1989. He advised companies such as Closure Medical Corporation, Novoste Corporation, Advanced Tissue Sciences Inc., Miravant Medical Technologies and Maxim Pharmaceuticals. He has more than thirty years of experience operating as a Money Manager, Financial Advisor and Merchant Banker. In 1981, he Co-founded ANA Financial Services, Inc. He founded Kriegsman Capital Group LLC. He serves as the Chairman of Kriegsman Capital Group LLC (The Kriegsman Group). He served as the Chairman of ANA Financial until 1989. He served as the Chairman of the He Board of Global Genomics since June 2000 until July 2002. He served as the Chairman at Kriegsman Capital Group LLC. He has been the Chairman of Cytrx Corporation since October 15, 2014. He served as a Director of Galena Biopharma, Inc., since 2006 until June 2016. He served as a Director at Catasys, Inc. from February 2014 to September 24, 2015. He has been a Director of Cytrx Corporation since July 2002. He served as an Independent Director at Bradley Pharmaceuticals Inc., since June 2003 until February 2008. He served as a Director of Authentidate Holding Corp., from December, 1997 to 2004. He has advised such companies as SuperGen Inc., Closure Medical Corporation, Novoste Corporation, Miravant Medical Technologies and Maxim Pharmaceuticals. He has been active in various charitable organizations including the Biotechnology Industry Organization, the ALS Association, the Los Angeles Venture Association, the Southern California Biomedical Council and the Palisades-Malibu YMCA. In February 2006, he received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association. He served as a Director of Hythiam Inc. until June 2009. He was formerly a Certified Public Accountant with KPMG in New York City. Mr. Kriegsman holds a B.S. degree from New York University in accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute.

Dr. Bruce M. Spiegelman, Ph.D., has been a Professor of Cell Biology at Dana-Farber Cancer Institute & Harvard Medical School since 1991. Dr. Spiegelman joined Harvard Medical School and the Dana-Farber Cancer Institute as an Assistant Professor. He was elected to the National Academy of Sciences in 2002. He served as the Chairman of Scientific Advisory Board, Member of Scientific Advisory Board and Director at Ember Therapeutics, Inc. Dr. Spiegelman has been a Member of Scientific Advisory Board of Araios, Inc. since December 2003. He serves as a Member of Scientific Advisory Board of Acceleron Pharma Inc. and CytRx Laboratories Inc. of CytRx Corporation. He also served as a Member of the Scientific Advisory Board at Elixir Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc. Dr. Spiegelman is the Recipient of the Heinrich Wieland Prize for Lipid Research from the University of Munich, the Rolf Luft Award from the Karolinska Institute, the Bristol-Myers Squibb Award for Outstanding Achievement in Metabolic Research and the Elliot P. Joslin Medal for Diabetes Research. Dr. Spiegelman holds a B.S. with highest honors from the College of William and Mary and a Ph.D. from Princeton University. His graduate work was immediately followed by postdoctoral research at the Massachusetts Institute of Technology.

Dr. Luciano Rossetti, M.D. serves as the Head of Global Research and Development at EMD Serono, Inc. Dr. Rossetti serves as Global Head of Research & Development and Executive Vice President at Merck Serono S.A. He has been Global Head of Research & Development for Biopharmaceutical Division and Executive Vice President at Merck KGaA since July 21, 2014. He served as Senior Vice President Late Stage Development at Merck Sharp & Dohme, or MSD. He was responsible for the entire clinical development from Phase II to Phase V across all therapeutic areas. At MSD, he played a key role in shaping and implementing the development strategy of several potential breakthrough compounds such as Anti PD-1. He also restructured the clinical genetics group to better leverage the collaboration between discovery and clinical development. Mr. Rossetti served as Senior Vice President of Merck & Co., Inc. and Franchise Head of Diabetes and Obesity Merck Research Laboratories (MRL) for Merck & Co., Inc. since September 1, 2006. Dr. Rossetti joined MRL after 18 years at Albert Einstein College of Medicine of Yeshiva University in the Bronx, New York, where he served as Professor of Medicine and Professor of Molecular Pharmacology, while holding the Judy R. and Alfred A. Rosenberg Endowed Chair in Diabetes Research. Since 2002, he also served as the Director of Einstein Diabetes Research Center. In this newly-created position, Mr. Rossetti has overall responsibility for scientific direction across the drug discovery and development process for Merck & Co., Inc.'s key therapeutic areas of diabetes and obesity. Dr. Rossetti serves as a Member of Scientific Advisory Board at CytRx Laboratories Inc., a Subsidiary of CytRx Corporation. In 2000, Dr. Rossetti received the Prestigious Outstanding Scientific Achievement Award of the American Diabetes Association in recognition of groundbreaking research in diabetes that demonstrates independence of thought and originality. This award is sponsored by Eli Lilly and Company and he presented the Lilly Lecture, entitled 'The Dialogue between Fat and Brain: Its Role in Nutrient Sensing and Insulin Resistance.' Dr. Rossetti has made major contributions to the understanding of the biochemical and molecular mechanism mediating the sensing of nutrients and, more recently, the role of leptin in the regulation of glucose and fat metabolism. He is an expert in the application of molecular genetics and pharmacological approaches to studies on appetite control by the hypothalamus. He holds a Doctorate in Medicine from the Trieste University Medical School, Italy. Dr. Rossetti received his Medical Training at Trieste University Medical School, and completed his intern/residence in internal medicine at Rome University Medical School in Italy. He also carried out Postdoctoral Research in the Department of Internal Medicine, Section of Endocrinology, at Yale University Medical School in New Haven, Connecticute.

Mr. John Y. Caloz has been the Chief Financial Officer of CytRx Corporation since January 2009. Mr. Caloz has been Chief Accounting Officer of CytRx Corporation since joining in October 2007 and serves as its Treasurer. He served as Chief Financial Officer and Treasurer of Occulogix Inc. from June 1, 2005 to April 2006. He has an accomplished history of providing senior financial leadership in the life sciences sector. Mr. Caloz served as Corporate Vice President, Chief Financial Officer and Corporate Secretary of IRIS International Inc. (formerly International Remote Imaging Systems Inc.) from August 2001 to December 1, 2003. Prior to joining IRIS, Mr. Caloz served as Chief Financial Officer of Synarc Inc., of San Francisco, CA. From 1993 to 1999, he served as Senior Vice President of Finance and Chief Financial Officer of Phoenix International Life Sciences Inc. of Montreal, QC and Irvine, CA. From 1983 to 1993, Mr. Caloz served as Partner of Rooney, Greig, Whitrod, Filion & Assoc. of Saint Laurent, Quebec, Canada. He is a Chartered Accountant and holds a B.A. degree in Accounting from York University, Toronto, Canada.